$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000117184321003310 Filed on May 07, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$19.06M	$4.823M
YoY Change	295.17%	-18.07%
Cost Of Revenue	$5.923M	$0.00
YoY Change		-100.0%
Gross Profit	$13.14M	$4.823M
YoY Change	172.36%	7.46%
Gross Profit Margin	68.92%	100.0%
Selling, General & Admin	$22.11M	$15.87M
YoY Change	39.39%	154.33%
% of Gross Profit	168.35%	328.94%
Research & Development	$42.44M	$29.87M
YoY Change	42.08%	8.63%
% of Gross Profit	323.04%	619.26%
Depreciation & Amortization	$178.0K	$218.0K
YoY Change	-18.35%	23.86%
% of Gross Profit	1.36%	4.52%
Operating Expenses	$64.55M	$45.73M
YoY Change	41.15%	35.58%
Operating Profit	-$51.38M	-$40.98M
YoY Change	25.38%	39.71%
Interest Expense	$12.90M	$3.047M
YoY Change	323.5%	11.78%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$64.28M	-$37.60M
YoY Change	70.97%	21.1%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$64.28M	-$37.60M
YoY Change	70.97%	21.08%
Net Earnings / Revenue	-337.29%	-779.58%
Basic Earnings Per Share	-$0.36
Diluted Earnings Per Share	-$362.5K	-$243.9K
COMMON SHARES
Basic Shares Outstanding	177.2M	154.2M
Diluted Shares Outstanding	177.3M	154.2M

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$240.4M	$113.1M
YoY Change	112.6%	5.11%
Cash & Equivalents	$226.9M	$101.9M
Short-Term Investments	$13.45M	$11.19M
Other Short-Term Assets	$9.900M	$6.800M
YoY Change	45.59%	51.11%
Inventory	$5.113M
Prepaid Expenses
Receivables	$18.39M	$5.642M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$273.8M	$125.5M
YoY Change	118.13%	6.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.035M	$7.270M
YoY Change	-3.23%	-4.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.625M	$3.811M
YoY Change	-4.88%	-29.29%
Total Long-Term Assets	$10.66M	$11.08M
YoY Change	-3.8%	-55.12%
TOTAL ASSETS
Total Short-Term Assets	$273.8M	$125.5M
Total Long-Term Assets	$10.66M	$11.08M
Total Assets	$284.4M	$136.6M
YoY Change	108.24%	-4.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.53M	$10.06M
YoY Change	34.47%	45.08%
Accrued Expenses	$32.72M	$20.19M
YoY Change	62.04%	22.03%
Deferred Revenue
YoY Change
Short-Term Debt	$30.00M	$29.70M
YoY Change	1.01%	1.71%
Long-Term Debt Due		$14.00M
YoY Change
Total Short-Term Liabilities	$101.2M	$92.70M
YoY Change	9.17%	39.76%
LONG-TERM LIABILITIES
Long-Term Debt	$123.0M	$36.50M
YoY Change	237.09%	-26.41%
Other Long-Term Liabilities	$3.900M	$3.700M
YoY Change	5.41%	-4.86%
Total Long-Term Liabilities	$123.0M	$40.20M
YoY Change	206.07%	933.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$101.2M	$92.70M
Total Long-Term Liabilities	$123.0M	$40.20M
Total Liabilities	$224.2M	$132.9M
YoY Change	68.73%	89.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.088B	-$878.2M
YoY Change	23.85%	15.13%
Common Stock	$1.777M	$1.542M
YoY Change	15.24%	39.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$74.99M	$3.648M
YoY Change
Total Liabilities & Shareholders Equity	$284.4M	$136.6M
YoY Change	108.24%	-4.04%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$64.28M	-$37.60M
YoY Change	70.97%	21.08%
Depreciation, Depletion And Amortization	$178.0K	$218.0K
YoY Change	-18.35%	23.86%
Cash From Operating Activities	-$61.01M	-$23.28M
YoY Change	162.06%	-13.77%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$120.0K
YoY Change	-16.67%	33.33%
Acquisitions
YoY Change
Other Investing Activities	$14.77M	$10.84M
YoY Change	36.25%	-32.12%
Cash From Investing Activities	$14.67M	$10.72M
YoY Change	36.82%	-32.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.900M	$266.0K
YoY Change	990.23%	-98.67%
NET CHANGE
Cash From Operating Activities	-$61.01M	-$23.28M
Cash From Investing Activities	$14.67M	$10.72M
Cash From Financing Activities	$2.900M	$266.0K
Net Change In Cash	-$43.44M	-$12.29M
YoY Change	253.41%	-237.75%
FREE CASH FLOW
Cash From Operating Activities	-$61.01M	-$23.28M
Capital Expenditures	-$100.0K	-$120.0K
Free Cash Flow	-$60.91M	-$23.16M
YoY Change	162.99%	-13.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	177696474
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177670000
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177670000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	176883000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176883000
CY2021Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	193000
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	593000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	-0	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	226902000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272127000	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4008000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2221000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13454000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28239000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18386000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8646000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	5113000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7039000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5908000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5528000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	273771000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	323800000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7035000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7113000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3625000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3802000	USD
CY2021Q1	us-gaap	Assets Assets	284431000	USD
CY2020Q4	us-gaap	Assets Assets	334715000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13529000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18713000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32719000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33942000	USD
CY2021Q1	us-gaap	Interest Payable Current InterestPayableCurrent	23547000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	21670000	USD
CY2021Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	405000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	150000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1001000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1179000	USD
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent	30000000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	30000000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	101201000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105654000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3883000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3871000	USD
CY2021Q1	bcrx	Future Royalties Payable FutureRoyaltiesPayable	131296000	USD
CY2020Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	124717000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	123039000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	119735000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	1777000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1769000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1010779000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1002408000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	182000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1087726000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1023442000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-74988000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-19262000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42435000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29867000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22114000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-37599000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	178000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-25000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64105000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37624000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284431000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	334715000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19059000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4823000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5923000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15865000	USD
CY2021Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	-36000	USD
CY2020Q1	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	69000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	70436000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	45801000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-51377000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40978000	USD
CY2021Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	26000	USD
CY2020Q1	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	6446000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	12904000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	3047000	USD
CY2021Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-29000	USD
CY2020Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-20000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	177343000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154156000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-37599000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	178000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5479000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2754000	USD
CY2021Q1	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	7536000	USD
CY2020Q1	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	0	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	3549000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021Q1	bcrx	Increase Decrease In Amortization Of Debt Issuance Costs IncreaseDecreaseInAmortizationOfDebtIssuanceCosts	-58000	USD
CY2020Q1	bcrx	Increase Decrease In Amortization Of Debt Issuance Costs IncreaseDecreaseInAmortizationOfDebtIssuanceCosts	341000	USD
CY2021Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	14000	USD
CY2020Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	4000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-0	USD
CY2020Q1	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-20000	USD
CY2021Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	261000	USD
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-16504000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1927000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9850000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	847000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7373000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5100000	USD
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1877000	USD
CY2020Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1477000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	255000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1053000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-61011000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23281000	USD
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	99000	USD
CY2020Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	116000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	14771000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10840000	USD
CY2021Q1	bcrx	Proceeds From Realized Gain On Investments ProceedsFromRealizedGainOnInvestments	1000	USD
CY2020Q1	bcrx	Proceeds From Realized Gain On Investments ProceedsFromRealizedGainOnInvestments	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14673000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10724000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2900000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2900000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	266000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43438000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12291000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274348000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115723000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	230910000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103432000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-19262000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-64284000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	179000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	723000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2177000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5479000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-74988000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	38252000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-37599000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-25000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2754000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	3648000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	13433000	USD
CY2021Q1	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	17000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13454000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	28211000	USD
CY2020Q4	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	25000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	28239000	USD
CY2021Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	8504000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8243000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	101000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	206000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	5012000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2555000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	270000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4548000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	5383000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7309000	USD
CY2021Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	270000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	270000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	5113000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7039000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	584000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	582000	USD
CY2021Q1	bcrx	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	7327000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10866000	USD
CY2021Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	11612000	USD
CY2021Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	417000	USD
CY2021Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	1000	USD
CY2020Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19059000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4823000	USD
CY2021Q1	us-gaap	Advertising Expense AdvertisingExpense	1404000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5982000	USD
CY2021Q1	bcrx	Operating Lease Rightofuse Asset Accumulated Amortization OperatingLeaseRightofuseAssetAccumulatedAmortization	2940000	USD
CY2020Q4	bcrx	Operating Lease Rightofuse Asset Accumulated Amortization OperatingLeaseRightofuseAssetAccumulatedAmortization	2641000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	902000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	666000	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	12904000	USD
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3047000	USD
CY2021Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	-58000	USD
CY2020Q1	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	341000	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	22044
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.50
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23741
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12196
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, the ORLADEYO royalty financing and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y4M24D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.128	pure
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	452000	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	448000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	440000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	408000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	805000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	108096000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5479000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2754000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	59329000	USD
CY2021Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	14490000	USD
CY2021Q1	bcrx	Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear	18299000	USD
CY2021Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	14511000	USD

Files In Submission

Name	View Source	Status
0001171843-21-003310-index-headers.html	Edgar Link	pending
0001171843-21-003310-index.html	Edgar Link	pending
0001171843-21-003310.txt	Edgar Link	pending
0001171843-21-003310-xbrl.zip	Edgar Link	pending
bcrx-20210331.xsd	Edgar Link	pending
bcrx-20210331_cal.xml	Edgar Link	unprocessable
bcrx-20210331_def.xml	Edgar Link	unprocessable
bcrx-20210331_lab.xml	Edgar Link	unprocessable
bcrx-20210331_pre.xml	Edgar Link	unprocessable
bcrx20210331_10q.htm	Edgar Link	pending
bcrx20210331_10q_htm.xml	Edgar Link	completed
ex_245740.htm	Edgar Link	pending
ex_245741.htm	Edgar Link	pending
ex_245742.htm	Edgar Link	pending
ex_245743.htm	Edgar Link	pending
ex_247203.htm	Edgar Link	pending
ex_247204.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2021 Q1 Form 10-Q Financial Statement

#000117184321003310 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2021 Q1 Form 10-Q Financial Statement

#000117184321003310 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx